RECRUITING

Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.

Official Title

Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population

Quick Facts

Study Start:2023-01-15
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05562778

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 8 years of age or older.
  2. * Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English.
  3. * Access to a telephone with texting capacity.
  4. * Has not had prior genetic testing for hereditary cancer syndromes.
  1. * Under 18 years of age
  2. * Has had previous genetic testing for hereditary cancer syndromes
  3. * Does not read/speak in English
  4. * Does not have access to a phone with texting capabilities

Contacts and Locations

Study Contact

Melissa K Frey, MD, MS
CONTACT
212-746-3049
mkf2002@med.cornell.edu
Isabelle Chandler
CONTACT
212-746-3049
irc4005@med.cornell.edu

Principal Investigator

Melissa K Frey, MD
PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University

Study Locations (Sites)

NYP Brooklyn Methodist Hospital
Brooklyn, New York, 11215
United States
NYP Lower Manhattan Hospital
New York, New York, 10038
United States
Weill Cornell Medicine
New York, New York, 10065
United States
NYP Medical Group Queens
Queens, New York, 11375
United States

Collaborators and Investigators

Sponsor: Weill Medical College of Cornell University

  • Melissa K Frey, MD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-15
Study Completion Date2025-12

Study Record Updates

Study Start Date2023-01-15
Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

  • Gynecologic Cancer
  • Hereditary Cancer Syndrome